Bolt Biotherapeutics has raised $120.0M in Series D funding. The clinical-stage immuno-oncology company is developing cancer therapies that harness the immune system, built around its proprietary Boltbody ISAC platform, which pairs tumor-targeting antibodies with immune stimulators to activate myeloid cells and drive anti-tumor responses.
The round drew Deep Track Capital, ADAR1 Capital, Andreessen Horowitz, Lyfe Capital, Coastlands Capital, Eventide Asset Management, Casdin Capital, Curie.Bio, SilverArc Capital, Soleus Capital and Deviation Capital. Bolt is advancing a pipeline of ISAC candidates including BDC-3042, CEA ISAC and PD-L1 ISAC, and the raise comes alongside its acquisition of Prana Therapies.
